Empyrean Medical Systems, in close partnership with the University of California, San Diego, is developing a novel pipeline of unique therapeutic compounds to transform the field of cancer treatment.
Our drug development pipeline includes a tumor-selective small molecule radiosensitizer for chemotherapy and radiotherapy of a wide range of solid malignancies and a radio-activated tumor-selective drug delivery platform.

Empyrean’s Therapeutics Division is operating and conducting its therapeutics research and development at the UCSD Center for Novel Therapeutics to advance these candidates to pre-IND studies and subsequent clinical trials. Empyrean is also developing a unique, orally bioavailable, and well-tolerated small molecule inhibitor for the treatment of brain and pancreatic cancers that has thus far shown promising activity.